Interaction Checker

Interacciones de Macitentán

Macitentán (Opsumit) tiene 117 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 77; moderadas: 0; leves: 40; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (77)

  • AmiodaronaantiarrítmicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • AtazanavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Cannabidiol (con receta)anticonvulsivoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • CapecitabinaantimetabolitoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • CiclosporinainmunosupresorGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • ClobazambenzodiazepinaGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Disulfiraminhibidor de CYP2C9Grave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • EfavirenzantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • FluorouraciloantimetabolitoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • FluvastatinaestatinaGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • FosamprenavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • IsoniazidaantibióticoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • LenacapavirantirretroviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • MetronidazolantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Miconazolantifúngico azólicoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • NevirapinaantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Nitisinonainhibidor de CYP2C9Grave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • PerampanelanticonvulsivoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • RifabutinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Subcitrato de bismuto, metronidazol y tetraciclinaantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Sulfametoxazol y trimetoprimasulfonamidaGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Grave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoGrave

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • TrimetoprimaantibióticoGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (etiqueta de Macitentán, Interacciones medicamentosas)

  • Zafirlukastantagonista de los receptores de leucotrienosGrave

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

Menciones leves (40)

  • Acetazolamidainhibidor de la anhidrasa carbónicaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Bumetanidadiurético de asaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Clorotiazidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Estradiol y dienogestanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Furosemidadiurético de asaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Levonorgestrel y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • NoretisteronaprogestágenoLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Noretisterona y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Norgestimato y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Norgestrel y etinilestradiolanticonceptivo oralLeve

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (etiqueta de Macitentán, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECALeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Torasemidadiurético de asaLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioLeve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Macitentán, Advertencias y precauciones)

Compruebe Macitentán frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.